secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001558370-25-003036
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix FY 2024: Record product revenue $53M (+31%), net income $2.9M; debt-free
--------------------------------------------------------------------------------

- Revenue from goods $53.0M (+31% YoY), driven by Chiesi sales (+$11.8M); total revenue $53.4M vs $65.5M in 2023.
- Net income $2.9M ($0.04/sh diluted) vs $8.3M ($0.12/sh basic) in 2023; lower due to absence of $20M milestone.
- Cash $34.8M; convertible notes fully repaid Sep 2024; no warrants remaining after March 2025 expiration.
- PRX-115 (gout) phase I completed; phase II expected H2 2025; EMA validated less frequent dosing for pegunigalsidase alfa.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025003036/0001558370-25-003036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837025003036/plx-20250317x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer